Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.

A clinical, morphological and neurochemical correlative study in patients with Parkinson's syndrome and Huntington's chorea is reported. In the former grou...

H Bernheimer，W Birkmayer，O Hornykiewicz，... - 《Journal of the Neurological Sciences》

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease.

BACKGROUND AND METHODS: In 1987 we began a multicenter controlled clinical trial of deprenyl (a monoamine oxidase inhibitor) and tocopherol (a component of...

None - 《New England Journal of Medicine》

Increased life expectancy resulting from addition of l-deprenyl to Madopar treatment in Parkinson's disease: A longterm study

In an open, uncontrolled study the longterm (9 years) effect of treatment with Madopar alone (n = 377) or in combination with l-deprenyl (selegiline, selective monoamine oxidase type B inhibitor) (n = 564) have been compared in Parkinson...

W Birkmayer，J Knoll，P Riederer，... - 《Journal of Neural Transmission》

The Norton Lecture: a review of the oligodendrocyte in the multiple sclerosis lesion

The mechanisms involved in the elimination of oligodendrocytes and myelin from the demyelinated plaque of multiple sclerosis (MS) are inextricably intertwi...

Cedric，S，Raine - 《Journal of Neuroimmunology》

Use of deprenyl analogues to maintain, prevent loss, or recover nerve cell function

The present invention relates to the use of deprenyl or derivatives or analogues of deprenyl to maintain, prevent loss and/or recover nerve cell function in an animal; to pharmaceutical compositions containing deprenyl adapted for such u...

WG Tatton，CE Greenwood - EP

Used for treament of hypoxia, ischemia, stroke and trauma; nervous system disorders

The present invention relates to the use of deprenyl or derivatives or analogues of deprenyl to rescue damaged nerve cells in an animal; to pharmaceutical ...

WG Tatton，CE Greenwood - US

Selegiline and Parkinson's disease: it's déjà vu-again.

No Abstract available for this article.

Lawrence I. Golbe，JW Langston，I Shoulson - 《Neurology》

The potentiation of the anti akinetic effect after L-Dopa treatment by an inhibitor of Mao-B, deprenil

The potentiation of the ami akinetic effect after L-Dopa treatment by an inhibitor of monoamine oxidase (MAO) "B", Deprenil, has been demonstrated in parkinsonian patients with or without previous L-Dopa therapy. Application of the drug ...

W Birkmayer，P Riederer，MBH Youdim，... - 《Journal of Neural Transmission》

DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group.

DATATOP (Deprenyl and tocopherol antioxidative therapy of parkinsonism) is a placebo-controlled clinical trial designed to test the hypothesis that long-te...

PS Group - 《Archives of Neurology》

The Norton Lecture: a review of the oligodendrocyte in the multiple sclerosis lesion.

The mechanisms involved in the elimination of oligodendrocytes and myelin from the demyelinated plaque of (MS) are inextricably intertwined and yet most in...

CS Raine - 《Journal of Neuroimmunology》